Celsis turnaround set to continue

5 June 2001

Celsis International of the UK says that turnover for the year to March2001 increased 6% to L17.5 million ($24.8 million), helped by a strong recovery in the second half of the year from the firm's products business. Operating profits before tax, interest and exceptionals reached L1.9 million, compared with L600,000 for the year earlier, and the firm noted that profits at its Celsis Laboratory Group were up 50%.

Celsis' chief executive, Jay LeCoque, said that despite a difficult start to the year, a number of steps had been taken to turn around its business, "including a fundamental restructuring of the products division." As a result of these measures, he claimed that Celsis is now in a stronger position "to capitalize on its leading market position to deliver future sustainable growth." Mr LeCoque added that this will be achieved both organically and "through selective acquisitions."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight